V itamin D deficiency may be widespread globally, even in sunny countries (1) . In the latest Australian Health Survey, in which an assay standardized to the Vitamin D Standardization Program reference measurement protocol was used, the overall prevalence of vitamin D deficiency/ inadequacy (<50 nM; 2) in Australians aged 12 years and older was 23%, with less than 7% of the population estimated to be moderately or severely deficient (<30 nM; 3). The predominant source of vitamin D for most Australians is endogenous synthesis in the skin initiated by exposure to solar UV (UVB) radiation (4) . The absorption of UVB photons by 7-dehydrocholesterol in epidermal cells results in conversion first to previtamin D 3 and then to vitamin D 3 . Vitamin D (D 2 or D 3 ) can also be obtained through dietary sources such as oily fish and mushrooms and, increasingly, through oral supplementation. After oral ingestion, vitamin D is absorbed through the gut and then transported in chylomicrons to the liver (5) . Both ingested and endogenously synthesized vitamin D are hydroxylated in the liver to form 25- Vitamin D supplementation may be required to maintain vitamin D sufficiency when exposure to UVB radiation is limited, e.g., at high latitudes and/or during winter, and in people who wear clothing that covers most of the skin when outdoors. Vitamin D supplementation can be provided via oral or intramuscular (IM) routes and using daily dosing or a large bolus of vitamin D at less frequent intervals. Oral supplementation is most commonly used. Adherence to daily ingestion of vitamin D may be difficult, especially in elderly patients (8) . Optimal levels are typically achieved after approximately 2 months of daily oral supplementation (assuming an appropriate dose), and serum 25(OH)D concentration is then maintained at a relatively constant level (reviewed in ref. 9 ). Daily oral dosing at <3000 IU/day has not been associated with any adverse effects on bone health (10) . In contrast, a single oral treatment with a large bolus of 100 000-600 000 IU of vitamin D rapidly increased serum 25(OH)D concentrations for 1 to 2 months posttreatment, although these levels were not sustained (11, 12) . In addition, with very high doses of oral supplementation (≥400 000 IU vitamin D), side effects have been reported, including gastrointestinal tract complaints, hypercalcemia, and hypercalcinuria (11, 13) . In one study, in the first 3 months after oral supplementation with a large bolus of vitamin D 3 (500 000 IU) in elderly women, there was an increased rate of falls and fractures (14) .
An alternative means of administering high-dose vitamin D is via IM injection. The dynamics of changes in serum 25(OH)D level after IM injection differ to those after oral supplementation. Serum 25(OH)D levels increase at a slower rate (in response to IM treatment with 600 000 IU vitamin D 2 or D 3 ) as compared to oral supplementation (15) and can persist at levels greater than baseline for up to 12 months posttreatment (16) . However, evidence on the effect of an IM bolus of vitamin D on blood biochemistry is limited. Studies have shown no change in plasma ionized calcium or phosphate levels in the 30-120 days (15) or 4-12 months (16) after a single IM injection of highdose vitamin D 3 (600 000 IU). The earlier effects (<30 days) on blood biochemistry after a large IM bolus of vitamin D 3 have not been well described.
In this study, we examined the effects of a single IM injection of high-dose vitamin D 3 (600 000 IU) on several vitamin D metabolites and serum/plasma markers of bone metabolism, including calcium, phosphate, parathyroid hormone (PTH), and alkaline phosphatase, in 10 adult participants at baseline and at 1, 2, 3, 4, and 24 weeks postinjection. Because of the potential for high-dose therapy to substantially increase serum 25(OH) D levels, we hypothesized that this treatment would increase the concentration of minor vitamin D metabolites in blood, allowing them to be quantified.
Materials and Methods

Participants
Ten adult participants who were receiving an annual bolus of IM vitamin D 3 as part of routine clinical care for the treatment of previously diagnosed vitamin D deficiency were recruited from a general practitioner's clinical suite (by M. Zafir, The Surgery, Albany, Western Australia). The mean age of participants was 64 years, 60% were male, and the patients had been diagnosed with a range of medical conditions (Table 1) .
Bolus Vitamin D 3 Supplementation
As part of their standard clinical care, participants were given an IM injection of 600 000 IU of vitamin D 3 (D3 Forte; Biological Therapies, Melbourne, Australia) into the deltoid muscle of the upper arm. Participants were treated in November 2015 in the clinic, when the average UV Index (maximum for the day) for Albany was 9.
Sample Collection
Blood was drawn from participants immediately before injection (baseline), as well as at 1, 2, 3, 4, and 24 weeks postinjection. Blood samples were transported on ice to Perth a Age at the beginning of the study; mean age ± SD was 63.9 ± 18.1 (n = 10). b 60% of the participants were male.
(Western Australia), and serum and plasma were extracted at PathWest Laboratory Medicine (Sir Charles Gairdner Hospital, Perth, Western Australia). Samples were assayed fresh or stored at −80°C until analyzed. 
Measurement of Serum 25(OH)D
Measurement of Other Vitamin D Metabolites
A slightly modified LC-MS/MS method using the derivatizing agent DMEQ-TAD (17) , and adapted to include assay of vitamin D 3 
Measurement of Other Metabolites
Serum and plasma were extracted from blood samples, and, with urine, were tested as part of a routine pathology "fasting bone metabolic study" or "fasting calcium metabolism panel" at PathWest Laboratory Medicine between November 2015 and May 2016. This panel is used for investigation of calcium disorders, osteoporosis, or other metabolic bone disease, as described previously (19, 20) . Plasma and urine biochemistry, including total calcium, phosphate, alkaline phosphatase, and plasma creatinine, were measured on the Abbott c16000 Clinical Chemistry Analyzer. Serum ionized calcium was measured using an ion-selective electrode on the ABL 800 FLEX analyzer (Radiometer, Copenhagen, Denmark). Plasma intact PTH was measured by electrochemiluminescence on the E170 (Roche Diagnostics GmbH, Mannheim, Germany).
Statistical Analyses
Data were compared using one-way analysis of variance (with Tukey's post hoc analysis), linear correlation (Pearson test), or a Bland-Altman analysis using the Prism 6.0 for Mac OS X statistical analysis program. Differences were considered significant with a P-value <0.05.
Ethics Approval
This study was performed according to the ethical guidelines of the Australian National Health and Medical Research Council and with approval from the Australian National University Human Research Ethics Committee (No. 2015/643).
Results
Large IM Bolus of Vitamin D 3 Increased Serum Total 25(OH)D Levels 4 Weeks After IM Injection
As measured by LC-MS/MS, all participants had total 25(OH) D levels >50 nM at baseline ( Figure 1A ). Total 25(OH)D levels significantly increased from baseline to 4 weeks postinjection ( Figure 1A) .
Large IM Bolus of Vitamin D 3 Modified Serum Calcium, but not Alkaline Phosphatase, PTH, or Phosphate
Serum ionized calcium levels were increased from baseline at 1, 3, and 4 weeks postinjection ( Figure 1B ) but were largely maintained within the normal clinical range (1.12-1.32 mM; Figure 2A ). By 24 weeks, the serum calcium levels were not significantly different to baseline (data not shown). At baseline, ionized serum calcium levels were below the normal clinical range for one individual (participant 5), but these were normalized by the IM vitamin D 3 by 1 week postinjection.
PTH levels were not significantly changed after vitamin D 3 treatment ( Figure 1C ), including at the 24-week time point (data not shown), and were maintained within the clinically normal range (1.6-6.9 pM; Figure 2B ). As has been previously reported (21) , there was a significant nonlinear relationship (second-order polynomial, quadratic r 2 = 0.156, P < 0.05) between plasma PTH and serum total 25(OH)D levels. This weak correlation is consistent with the variable findings around this relationship as reviewed and reported by the U.S. Institute of Medicine (IOM; 2). Other biochemical parameters were unchanged by the high-dose injection, including plasma levels of alkaline phosphatase ( Figure 1D ), phosphate ( Figure 1E ), albumin, and creatinine, as well as urinary markers including creatinine, calcium, phosphate, and the calcium/creatinine excretion index (data not shown).
IM Injection of High-Dose Vitamin D Had Modest Effects on Other Serum Vitamin D Metabolites
The results from the LC-MS/MS assay showed that there was an increase in total 25(OH)D ( Figure 1A ) and 25(OH)D 3 ( Figure 3A ) at 4 weeks postinjection, with a nonsignificant decrease in 25(OH)D 2 ( Figure 3B ). Serum vitamin D 3 ( Figure 3C ) and 3-epi-25(OH)D 3 ( Figure 3D ) appeared to increase from baseline, but this increase was not statistically significant. Levels of 24,25(OH) 2 D 3 were significantly increased from baseline at 3 and 4 weeks postinjection ( Figure 3E 
Modest Correlation Between 25(OH)D Levels as Measured by Immunoassay and Total 25(OH)D as Measured with the Standardized LC-MS/MS Assay
Data for 25(OH)D levels for the 24-week time point were available only for the immunoassay. This immunoassay is typically used by doctors in their clinical management of patients; therefore, understanding the change in 25(OH)D levels that would be seen in clinical practice is of value. We assessed the accuracy of the immunoassay as compared to the standardized reference assay. There was a significant (but weak) correlation between 25(OH)D levels measured using the immunoassay and total 25(OH)D levels measured using LC-MS/MS ( Figure 4A ). There was a positive bias of 13.3 nM, with higher 25(OH)D levels measured using the immunoassay compared to the LC-MS/MS assay ( Figure 4B ).
Serum 25(OH)D Peaked 4 Weeks After IM Injection, with Levels Remaining Higher than Baseline at 24 Weeks Posttreatment
At baseline, 25(OH)D levels measured in serum using the immunoassay were >50 nM, peaking at 4 weeks postinjection for most participants ( Figure 4C ). At 24 weeks postinjection, serum 25(OH)D levels were still significantly greater than baseline ( Figure 4C ).
Discussion
In this study, we undertook detailed monitoring of changes in vitamin D and its metabolites and in bone-related parameters measured in serum/plasma and urine immediately before and after a single large IM bolus of vitamin D 3 (600 000 IU). After a large IM bolus, there was a modest and sustained increase in serum 25(OH)D 3 levels and elevated metabolism of 25(OH)D 3 , as shown by the increase in levels of the breakdown product, 24,25(OH) 2 D 3 . There was an increase in serum levels of ionized calcium within the normal range. There were no significant changes in other markers of bone metabolism in blood or urine.
The active form of vitamin D, 1,25(OH) 2 D plays a critical role in bone metabolism through regulation of calcium and phosphate homeostasis. Falling calcium levels stimulate the release of PTH, which, in turn, upregulates the conversion of 25(OH)D to 1,25(OH) 2 D. The latter enhances the intestinal uptake and renal retention of calcium and the immobilization of phosphate within bone (22) 2 D induces the mobilization of skeletal calcium from the bone matrix (causing an elevation of bonespecific alkaline phosphatase; 23) to restore blood calcium levels (24) . Thus, vitamin D is required for bone health; severe vitamin D deficiency results in loss of mineralization of bone, leading to rickets in children and osteomalacia in adults. Similarly, vitamin D toxicity manifests as hypercalcemia and hyperphosphatemia, and the suppression of PTH secretion has been explored as a marker of vitamin D adequacy (2) .
In a previous study, high-dose oral vitamin D supplementation modified bone metabolism and increased the incidence of falls Broken lines in (A) and (B) represent the clinically normal ranges for calcium and PTH, respectively. and fractures in the first few months post-treatment (14) . There is similar evidence suggesting that IM injection of vitamin D may perturb bone health in elderly people, although this effect may be sex specific. Although an annual IM injection of high-dose vitamin D 2 (150 000-300 000 IU) reduced the proportion of fractures in elderly male participants in comparison to that observed in a control group (25) , increased rates of hip fracture were observed in women (but not men) receiving an IM injection of 300 000 IU vitamin D 2 (compared to those receiving placebo; 26). Notably, we did not observe any early effects on alkaline phosphatase or PTH, and calcium levels remained within the normal range, although serum calcium levels increased during the first month after supplementation. In a study in which the incidence of increased falls was observed in elderly people administered higher monthly oral doses of vitamin D 3 (60 000 IU or 24 000 IU plus 300 μg calcifediol; 25(OH)D) compared to a control group (24 000 IU vitamin D 3 ), a transient increase in calcium excretion (in urine) was observed in the treatment groups (with no change in serum calcium; 27). Further studies examining the effects of high-dose vitamin D supplementation on biochemical markers of bone health in the months immediately after supplementation are needed.
One motivation for doing this study was to quantify the levels of minor vitamin D metabolites such as 25 concentration increased, also likely due to the induction of vitamin D catabolism through increased 24-hydroxylase enzyme activity.
Some limitations of the current study include the small sample size and the heterogeneous nature of the recruited population. Compared to daily supplementation, treatment with an IM bolus of vitamin D 3 is far less common as a treatment for vitamin D deficiency, limiting the size of the potential study population. Participants covered a wide age range (from 35 to 91 years) and were diagnosed with a range of conditions, some of which could affect aspects of vitamin D synthesis (e.g., underlying liver diseases like hemochromatosis). Therefore, it is not clear how applicable the findings here are to a healthy population, and further work is required to confirm that these findings are applicable more widely. A final caveat is that these participants were all vitamin D sufficient at baseline, and steeper changes in 25(OH)D level occur after supplementation when the baseline concentration is lower (11) .
On the basis of the results from this small study, this dosing strategy of a large IM bolus of vitamin D 3 appears to be safe and effective in raising and sustaining serum 25(OH)D levels, at least for a 24-week period, such as for maintaining vitamin D sufficiency through winter. The IM dosing gave a slower-thananticipated rise in total 25(OH)D levels, and all of the changes in biochemical parameters remained within the normal clinical ranges. None of the participants achieved total 25(OH)D levels (measured using the standardized reference assay) that exceeded the IOM guidelines for an upper limit (125 nM); however, the immunoassay had a positive bias of 13 nM, so clinicians testing follow-up vitamin D status may indeed record higher levels than in the IOM guidelines (2) . This variability underlines the importance of assay standardization and informing clinicians of the potential errors in the values returned from nonstandardized assays.
